Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.

• Main Authors: Dipika Sur (Author), Suman Kanungo (Author), Binod Sah (Author), Byomkesh Manna (Author), Mohammad Ali (Author), Allison M Paisley (Author), Swapan K Niyogi (Author), Jin Kyung Park (Author), Banawarilal Sarkar (Author), Mahesh K Puri (Author), Deok Ryun Kim (Author), Jacqueline L Deen (Author), Jan Holmgren (Author), Rodney Carbis (Author), Raman Rao (Author), Thu Van Nguyen (Author), Seung Hyun Han (Author), Stephen Attridge (Author), Allan Donner (Author), Nirmal K Ganguly (Author), Sujit K Bhattacharya (Author), G Balakrish Nair (Author), John D Clemens (Author), Anna Lena Lopez (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2011-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen o...